Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).
Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.
For more information, please call the Help Desk at 800-636-0316.
The information contained in this section of the site is intended for US specialty pharmacy representatives only. Click "OK" if you are a specialty pharmacy representative.
Eligible commercially insured patients who are prescribed Evrysdi for an FDA-approved use can receive up to $25,000 in assistance per 12-month period.
Due to privacy policies, specialty pharmacies that do not have an account must call (800) 636-0316 to create one.If you forgot your password, please call (800) 636-0316 to reset it.
Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.
Interactions with Substrates of MATE Transporters
Potential Effects on Male Fertility
Most Common Adverse Reactions
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see accompanying full Prescribing Information for additional Important Safety Information.